LACTNET Archives

Lactation Information and Discussion

LACTNET@COMMUNITY.LSOFT.COM

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
"Dr. Tom Hale" <[log in to unmask]>
Reply To:
Lactation Information and Discussion <[log in to unmask]>
Date:
Fri, 29 May 1998 17:06:05 -0400
Content-Type:
text/plain
Parts/Attachments:
text/plain (30 lines)
To : Jan Aiken
Re : Cabergoline (Dostinex)

From my new edition:

Cabergoline is a long-acting synthetic ergot alkaloid derivative which
produces a dopamine agonist effect similar but much safer than bromocriptine
(Parlodel).   Cabergoline directly inhibits prolactin secretion by the
pituitary.   It is primarily indicated for pathological hyperprolactinemia,
but in several European studies, it has been used for inhibition of post-
partum lactation.  In several European countries, cabergoline is indicated
for the inhibition or suppression of physiologic lactation.  The dose
regimen used for the inhibition of physiologic lactation is cabergoline 1 mg
administered as a single dose on the first day post-partum.   For the
suppression of established lactation,  cabergoline 0.25 mg is taken every 12
hours for 2 days for a total of 1 mg.   Single doses of 1 mg have been found
to completely  inhibit postpartum lactation.  Transfer into human milk is
not reported.






Regards

Tom Hale, Ph.D.

http://neonatal.ttuhsc.edu/lact/

ATOM RSS1 RSS2